

Amendments to the Specification:

Please amend the specification as follows:

Please delete the paragraph on page 4, lines 6-14 and replace it with the following paragraph:

In the context of the present invention, the term derivative or fragment of peptides further includes peptides which are shortened at their carboxyterminal end. The inventors have found that, for example, amino acids alanin, glutamic acid, isoleucin, tyrosin, glutamic acid, serin (A-E-I-Y-E-S) **(SEQ ID NO: 133)**, which are the last six carboxyterminal amino acids of most peptides of SEQ ID NOs: 87-132, can be omitted, without losing the characteristic functional properties of the respective peptides. However, it is also possible that the peptides of the present invention are carboxyterminally shortened by more than these six amino acid, provided that the binding and functional properties of the peptides remain unaffected.

Please delete the paragraph on page 15, lines 17-21 and replace it with the following paragraph:

Table 2 lists so-called linear peptides being not embedded in a thioredoxin A scaffold as it is commonly done for aptamers **(SEQ ID NOS 87-132, respectively, in order or appearance)**. Linear peptide banks are generated by expressing randomized 20-mer peptides during a screening procedure as GAL4AD fusions (i.e. aminoterminally fused to the GAL4 activation domain). This results in peptides with a free carboxyterminal end.